BR112015023589A8 - Método para a produção de um conjugado de imunoligante/carga útil, conjugado, uso de um conjugado, carga útil de baixo peso molecular e uso de uma carga útil - Google Patents

Método para a produção de um conjugado de imunoligante/carga útil, conjugado, uso de um conjugado, carga útil de baixo peso molecular e uso de uma carga útil

Info

Publication number
BR112015023589A8
BR112015023589A8 BR112015023589A BR112015023589A BR112015023589A8 BR 112015023589 A8 BR112015023589 A8 BR 112015023589A8 BR 112015023589 A BR112015023589 A BR 112015023589A BR 112015023589 A BR112015023589 A BR 112015023589A BR 112015023589 A8 BR112015023589 A8 BR 112015023589A8
Authority
BR
Brazil
Prior art keywords
payload
conjugate
immunoligand
producing
molecular weight
Prior art date
Application number
BR112015023589A
Other languages
English (en)
Other versions
BR112015023589B1 (pt
BR112015023589A2 (pt
Inventor
Renzo Beerli Roger
Ulf Grawunder
Original Assignee
Nbe Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nbe Therapeutics Ag filed Critical Nbe Therapeutics Ag
Priority to BR122021025118-5A priority Critical patent/BR122021025118B1/pt
Publication of BR112015023589A2 publication Critical patent/BR112015023589A2/pt
Publication of BR112015023589A8 publication Critical patent/BR112015023589A8/pt
Publication of BR112015023589B1 publication Critical patent/BR112015023589B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/537—Protease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

método para a produção de um conjugado de imunoligante/carga útil, conjugado, carga útil de baixo peso molecular e uso de uma carga útil. a presente invenção refere-se a um método para a produção de um conjugado de imunoligante/carga útil, cujo método engloba conjugar uma carga útil a um imunoligante por meio de uma transpeptidase de sequência específica, ou um domínio catalítico da mesma (figura 6b).
BR112015023589-1A 2013-03-15 2014-03-14 Método para a produção de um conjugado de imunoligante/carga útil BR112015023589B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122021025118-5A BR122021025118B1 (pt) 2013-03-15 2014-03-14 Conjugado de imunoligante/carga útil

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361787371P 2013-03-15 2013-03-15
US61/787,371 2013-03-15
EP13159484.8 2013-03-15
EP13159484.8A EP2777714A1 (en) 2013-03-15 2013-03-15 Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
US201461939754P 2014-02-14 2014-02-14
US61/939,754 2014-02-14
PCT/EP2014/055173 WO2014140317A2 (en) 2013-03-15 2014-03-14 Method of producing an immunoligand/payload conjugate

Publications (3)

Publication Number Publication Date
BR112015023589A2 BR112015023589A2 (pt) 2017-10-24
BR112015023589A8 true BR112015023589A8 (pt) 2022-03-08
BR112015023589B1 BR112015023589B1 (pt) 2023-10-03

Family

ID=47900856

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112015023589-1A BR112015023589B1 (pt) 2013-03-15 2014-03-14 Método para a produção de um conjugado de imunoligante/carga útil
BR122021025118-5A BR122021025118B1 (pt) 2013-03-15 2014-03-14 Conjugado de imunoligante/carga útil

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122021025118-5A BR122021025118B1 (pt) 2013-03-15 2014-03-14 Conjugado de imunoligante/carga útil

Country Status (13)

Country Link
US (4) US9872923B2 (pt)
EP (2) EP2777714A1 (pt)
JP (3) JP7213610B2 (pt)
CN (3) CN109260478A (pt)
AU (1) AU2014230129B2 (pt)
BR (2) BR112015023589B1 (pt)
CA (1) CA2903581A1 (pt)
HK (1) HK1217296A1 (pt)
IL (3) IL240893B (pt)
MX (1) MX365547B (pt)
SG (2) SG11201507385YA (pt)
WO (1) WO2014140317A2 (pt)
ZA (1) ZA201506005B (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
KR101808223B1 (ko) * 2013-04-25 2017-12-13 주식회사 앱틀라스 자가 절단 카세트를 포함하는 단백질 정제 방법 및 이의 용도
EP3138568B1 (en) 2014-04-29 2019-04-17 Genequantum Healthcare (Suzhou) Co., Ltd. New stable antibody-drug conjugate, preparation method therefor, and use thereof
WO2016096740A1 (en) 2014-12-17 2016-06-23 F. Hoffmann-La Roche Ag Activity assay for bond forming enzymes
SG11201704627XA (en) 2014-12-17 2017-07-28 Hoffmann La Roche Enzymatic one-pot reaction for double polypeptide conjugation in a single step using sortase
CA2971634A1 (en) * 2014-12-23 2016-06-30 Nbe-Therapeutics Ag Binding protein drug conjugates comprising anthracycline derivatives
WO2016128410A1 (en) 2015-02-09 2016-08-18 Nbe Therapeutics Ag Maytansine-drug conjugates of her- 2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation
WO2016149464A1 (en) * 2015-03-17 2016-09-22 Regeneron Pharmaceuticals, Inc. Amino acid acylation reagents and methods of using the same
EP3353310B1 (en) 2015-09-25 2020-04-29 H. Hoffnabb-La Roche Ag Process for producing thioesters employing a sortase a
EP3353314A1 (en) 2015-09-25 2018-08-01 H. Hoffnabb-La Roche Ag Transamidation employing sortase a in deep eutectic solvents
JP6998862B2 (ja) 2015-09-25 2022-02-04 エフ．ホフマン－ラ ロシュ アーゲー 可溶性ソルターゼａ
SG11201803098VA (en) 2015-10-30 2018-05-30 Nbe Therapeutics Ag Anti-ror1 antibodies
EP3368577A1 (en) * 2015-10-30 2018-09-05 NBE-Therapeutics AG Anti-mesothelin antibodies
KR20180099887A (ko) 2016-01-20 2018-09-05 더 스크립스 리서치 인스티튜트 Ｒｏｒ2 항체 조성물 및 관련 방법
BR112018014615A2 (pt) 2016-01-20 2018-12-11 The Scripps Research Institute composições de anticorpo para ror1 e métodos relacionados
CN106397598B (zh) * 2016-02-23 2020-07-14 上海交通大学 多价多特异性抗体及免疫杂合蛋白的表达和制备方法
CN105925596A (zh) * 2016-02-23 2016-09-07 上海交通大学 基于内含肽的药用重组蛋白的合成方法
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
KR20230082055A (ko) 2016-06-17 2023-06-08 마젠타 테라퓨틱스 인코포레이티드 세포의 고갈을 위한 조성물 및 방법
EP3272864A1 (en) 2016-07-20 2018-01-24 Paul Scherrer Institut Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
MX2019008199A (es) 2017-01-06 2019-11-25 Avidity Biosciences Llc Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
WO2018134787A2 (en) 2017-01-20 2018-07-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd137+ cells
US20210139579A1 (en) 2017-07-20 2021-05-13 Nbe-Therapeutics Ag Multispecific antibody product that binds to different ror1 epitopes
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
SG11202000846WA (en) * 2017-08-07 2020-02-27 Nbe Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
CN111655268B (zh) 2017-10-04 2024-03-26 艾维迪提生物科学公司 核酸-多肽组合物及其用途
CN107759699A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd30抗原的转基因t细胞及其制备方法与应用
MA51103A (fr) 2017-12-06 2020-10-14 Avidity Biosciences Inc Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique
US20200407405A1 (en) * 2018-02-26 2020-12-31 Ohio State Innovation Foundation Split-immunotoxins for boosting oncolytic virus toxicity
WO2019173911A1 (en) 2018-03-13 2019-09-19 Zymeworks Inc. Anti-her2 biparatopic antibody-drug conjugates and methods of use
WO2019215207A1 (en) 2018-05-10 2019-11-14 Cis Pharma Ag Biocompatible copolymer containing multiple active agent molecules
CN108593909A (zh) * 2018-05-23 2018-09-28 苏州立禾生物医学工程有限公司 一种定点标记免疫试剂的方法、标记免疫试剂及应用
WO2020013126A1 (ja) * 2018-07-09 2020-01-16 国立大学法人 熊本大学 環状一本鎖抗体
WO2020048876A1 (en) * 2018-09-03 2020-03-12 Technische Universitaet Muenchen A double peptide tag combining reversibility and flexible functionalization
CN112888710B (zh) * 2018-09-30 2023-06-09 美国杰科实验室有限公司 一种多肽组合物
EP3636284A1 (en) 2018-10-11 2020-04-15 NBE Therapeutics AG Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
EP3647419A1 (en) 2018-11-02 2020-05-06 NBE Therapeutics AG Sortase f and its use in methods for conjugation
AU2019406199A1 (en) 2018-12-21 2021-07-29 Avidity Biosciences, Inc. Anti-transferrin receptor antibodies and uses thereof
EP3918323A4 (en) 2019-01-30 2022-12-28 TrueBinding, Inc. ANTI-GAL3 ANTIBODIES AND THEIR USES
KR20220144753A (ko) * 2019-03-19 2022-10-27 폴 슈레 앙스띠뛰 글리신 기반 링커를 사용한 트랜스글루타미나제 컨쥬게이션 방법
JP2022535588A (ja) 2019-06-06 2022-08-09 アビディティー バイオサイエンシーズ，インク． 核酸ポリペプチド組成物およびその使用
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
GB201914468D0 (en) 2019-10-07 2019-11-20 Crescendo Biologics Ltd Binding Molecules
CA3150503A1 (en) 2019-10-30 2021-05-06 Cis Pharma Ag BIOCOMPATIBLE POLYMERIC MEDICATION CARRIES FOR THE DELIVERY OF ACTIVE AGENTS
CN115666589A (zh) 2020-03-19 2023-01-31 艾维迪提生物科学公司 治疗面肩肱型肌营养不良的组合物和方法
TW202202173A (zh) 2020-03-27 2022-01-16 美商亞維代堤生物科學公司 治療肌肉萎縮症之組合物及方法
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
WO2022160156A1 (en) * 2021-01-28 2022-08-04 Genequantum Healthcare (Suzhou) Co., Ltd. Ligase fusion proteins and applications thereof
EP4308242A1 (en) 2021-03-17 2024-01-24 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
AU2022259314A1 (en) 2021-04-14 2023-11-30 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
CN115369127A (zh) * 2021-05-18 2022-11-22 苏州有诺真生物科技有限公司 一种基于基因改造脊椎动物的携带通用定点偶联接口的抗体的制备方法
EP4370555A1 (en) 2021-07-13 2024-05-22 TrueBinding, Inc. Methods of preventing protein aggregation
WO2023014360A1 (en) * 2021-08-05 2023-02-09 Octagon Therapeutics, Inc. Treatment and diagnosis of immune disorders relating to aberrant immune cells
KR20240043797A (ko) 2021-08-13 2024-04-03 싸이튠 파마 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합
CN113777295B (zh) * 2021-09-15 2024-03-19 江南大学 用于检测肿瘤标志物pd-l1的高灵敏度量子点探针、制备方法及应用
IL311452A (en) 2021-09-16 2024-05-01 Avidity Biosciences Inc Compositions and methods for the treatment of FSHD muscular dystrophy
WO2023122347A2 (en) 2021-12-23 2023-06-29 Mirecule, Inc. Compositions for delivery of polynucleotides
WO2023143319A1 (zh) * 2022-01-28 2023-08-03 启德医药科技（苏州）有限公司 抗体药物偶联物、药物组合物及用途
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024033362A1 (en) 2022-08-08 2024-02-15 Atb Therapeutics Humanized antibodies against cd79b
WO2024107765A2 (en) 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932523B (en) 1992-04-10 1994-10-08 Res Dev Foundation Immunotoxins directed against cd33 related surface antigens
JPH11506915A (ja) 1995-06-07 1999-06-22 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃｄ８０およびｃｄ８６発現細胞に対して特異的なイムノトキシン
WO2002046208A2 (en) * 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
DE10341812A1 (de) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2005051976A2 (en) * 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
EP2145954A1 (en) 2004-09-06 2010-01-20 Kyowa Hakko Kirin Co., Ltd. Anti-A33 antibody
ES2539126T3 (es) 2004-12-09 2015-06-26 Janssen Biotech, Inc. Inmunoconjugados anti integrina, métodos para su producción y su uso
DE102005061934A1 (de) 2005-12-23 2007-06-28 Philipps-Universität Marburg Verfahren zur Herstellung eines chemisch modifizierten Proteins
EP1996236A2 (en) 2006-03-22 2008-12-03 National Institute of Immunology Novel bioconjugates as therapeutic agent and synthesis thereof
US8993295B2 (en) * 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
JP5618172B2 (ja) * 2007-01-05 2014-11-05 国立大学法人東京大学 抗ｐｒｇ−３抗体を用いる癌の診断および治療
PT2211904T (pt) 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
EP2240495B1 (en) 2008-02-01 2015-07-15 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
ES2544682T3 (es) * 2008-03-14 2015-09-02 Genentech, Inc. Variaciones genéticas asociadas con la resistencia a fármacos
US8394604B2 (en) * 2008-04-30 2013-03-12 Paul Xiang-Qin Liu Protein splicing using short terminal split inteins
US8541178B2 (en) * 2008-05-13 2013-09-24 Genentech, Inc. Analysis of antibody drug conjugates by bead-based affinity capture and mass spectrometry
US8900589B2 (en) 2008-07-15 2014-12-02 Genetech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
CA2754531A1 (en) 2009-03-06 2010-09-30 Seattle Genetics, Inc. Antibody drug conjugates (adc) that bind to 24p4c12 proteins
JP2012523383A (ja) 2009-04-08 2012-10-04 ファウルシュティヒ，ハインツ がんの治療のためのアマトキシンと複合体形成した標的結合部分
JP2012528112A (ja) 2009-05-28 2012-11-12 グラクソ グループ リミテッド 抗原結合タンパク質
US20130122043A1 (en) * 2010-04-20 2013-05-16 Whitehead Institute For Biomedical Research Modified polypeptides and proteins and uses thereof
KR101897307B1 (ko) 2010-12-02 2018-09-10 네르비아노 메디칼 사이언시스 에스.알.엘. 모르폴리닐 안트라사이클린 유도체의 제조 방법
JP6261341B2 (ja) * 2011-02-01 2018-01-17 ゲンマブ エー／エス Ｃｄ７４に対するヒト抗体および抗体−薬物コンジュゲート
WO2012142659A1 (en) * 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
EP2524929A1 (en) * 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
US20140302084A1 (en) 2011-08-05 2014-10-09 The University Of Chicago Immunogenic protein conjugates and method for making and using the same
KR20130046322A (ko) 2011-10-27 2013-05-07 한국외국어대학교 연구산학협력단 식중독 세균 Salmonella enterica 탐지용 탐침자 및 그를 포함한 DNA 칩
KR101718200B1 (ko) 2012-05-21 2017-03-21 제넨테크, 인크. 항-Ly6E 항체 및 면역접합체 및 사용 방법
WO2013177231A1 (en) 2012-05-21 2013-11-28 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore
JP6321633B2 (ja) * 2012-06-04 2018-05-09 ノバルティス アーゲー 部位特異的標識法およびそれによって生成される分子
WO2014088928A1 (en) 2012-12-03 2014-06-12 President And Fellows Of Harvard College Methods for making targeted protein toxins by sortase-mediated protein ligation
EP2777714A1 (en) * 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
KR101808223B1 (ko) * 2013-04-25 2017-12-13 주식회사 앱틀라스 자가 절단 카세트를 포함하는 단백질 정제 방법 및 이의 용도
CN105722851A (zh) 2013-04-28 2016-06-29 秦刚 一种新型的连接子及其制备方法和用途

Also Published As

Publication number Publication date
JP7481852B2 (ja) 2024-05-13
JP2022130634A (ja) 2022-09-06
JP2016511279A (ja) 2016-04-14
NZ711762A (en) 2021-04-30
CN105142675B (zh) 2021-08-20
AU2014230129A1 (en) 2015-09-24
IL284979A (en) 2021-08-31
US20160136298A1 (en) 2016-05-19
US11986535B2 (en) 2024-05-21
US10864277B2 (en) 2020-12-15
EP2968583A2 (en) 2016-01-20
BR112015023589B1 (pt) 2023-10-03
EP2777714A1 (en) 2014-09-17
JP7213610B2 (ja) 2023-01-27
IL268423A (en) 2019-09-26
WO2014140317A2 (en) 2014-09-18
WO2014140317A8 (en) 2014-11-06
US11364301B2 (en) 2022-06-21
AU2014230129B2 (en) 2019-03-28
BR112015023589A2 (pt) 2017-10-24
AU2014230129A8 (en) 2016-04-14
IL240893A0 (en) 2015-10-29
US9872923B2 (en) 2018-01-23
JP2020089383A (ja) 2020-06-11
US20210015936A1 (en) 2021-01-21
IL284979B (en) 2022-06-01
IL240893B (en) 2019-08-29
CA2903581A1 (en) 2014-09-18
US20220378927A1 (en) 2022-12-01
MX2015012983A (es) 2016-04-04
IL268423B (en) 2021-08-31
SG10201903962PA (en) 2019-05-30
WO2014140317A3 (en) 2014-12-24
US20190262461A1 (en) 2019-08-29
ZA201506005B (en) 2016-10-26
CN105142675A (zh) 2015-12-09
CN113908291A (zh) 2022-01-11
CN109260478A (zh) 2019-01-25
MX365547B (es) 2019-06-07
HK1217296A1 (zh) 2017-01-06
BR122021025118B1 (pt) 2023-10-10
SG11201507385YA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
BR112015023589A8 (pt) Método para a produção de um conjugado de imunoligante/carga útil, conjugado, uso de um conjugado, carga útil de baixo peso molecular e uso de uma carga útil
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
GT201600086A (es) Pirrolo[12-f][1,2,4]triazinas útiles para tratar infecciones por el virus sincitial respiratorio
MX2019011926A (es) Metodos utiles en la sintesis de analogos de halicondrina b.
EA201690372A1 (ru) Азапиридоновые соединения и их применение
PE20160870A1 (es) Anticuerpos anti-claudina novedosos y metodos de uso
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CR20150048A (es) Anticuerpos e inmunoconjugados anti-cd22
BR112014020826A2 (pt) moduladores e métodos de uso
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
BR112013023015A2 (pt) conjungado de amatoxina e seu uso, composição farmacêutica e seu uso, molécula de conjugação de amatoxina, método para a síntese de um conjungado de amatoxina.
BR112016004245A2 (pt) moduladores de sez6 e métodos de uso
BR112015025347A2 (pt) 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CY1122822T1 (el) Σακχαριτες παραγωγοποιημενοι με κυκλοαλκινιο
BR112016007279A2 (pt) junta de compensação de retorno para veículos ferroviários
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
UY34579A (es) Dispositivo de inhalación para fármacos en polvo
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
UY34580A (es) Dispositivo de inhalación para fármacos en polvo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/00 (2006.01), C07K 1/107 (2006.01), C07K 1

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS